Adaptive Biotechnologies Financial Statements
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adaptive Biotechnologies revenue and earnings
In fiscal 2025, Adaptive Biotechnologies generated $277.0 million in revenue, up 54.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Adaptive Biotechnologies reported a net loss of $59.5 million, compared with a loss of $159.5 million a year earlier. Gross margin was 74.2% (up from 59.7%) and operating margin -20.6%.
Diluted earnings per share came in at -$0.39. Over the last 5 fiscal years, ADPT's revenue has grown at a 23.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Adaptive Biotechnologies income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 276.98M | 178.96M | 170.28M | 185.31M | 154.34M | 98.38M | 85.07M | 55.66M | 38.45M |
| Revenue growth (YoY) | +54.77% | +5.10% | -8.11% | +20.06% | +56.88% | +15.65% | +52.83% | +44.77% | — |
| Cost of Revenue | 71.36M | 72.08M | 75.55M | 57.91M | 49.30M | 22.53M | 22.27M | 19.67M | 15.68M |
| Gross Profit | 205.62M | 106.88M | 94.72M | 127.40M | 105.04M | 75.85M | 62.80M | 35.99M | 22.77M |
| Operating Expenses | 262.74M | 269.43M | 321.76M | 327.58M | 314.01M | 228.67M | 141.19M | 85.75M | 67.24M |
| Research & Development | 93.77M | 102.95M | 122.12M | 141.76M | 142.34M | 116.07M | 70.70M | 39.16M | 32.00M |
| Selling, General & Admin | 167.27M | 157.56M | 172.51M | 184.13M | 169.97M | 110.89M | 68.78M | 44.90M | 32.71M |
| Operating Income | -57.12M | -162.55M | -227.03M | -200.19M | -208.97M | -152.82M | -78.39M | -49.76M | -44.48M |
| Interest Expense | 11.78M | 11.58M | 13.80M | 4.24M | — | — | — | — | — |
| Pretax Income | -59.46M | -159.59M | -225.30M | -200.37M | -207.30M | -146.23M | -68.61M | — | — |
| Income Tax | 0 | 0 | 0 | — | — | — | 0 | — | — |
| Net Income | -59.50M | -159.49M | -225.25M | -200.19M | -207.28M | -146.23M | -68.61M | -46.45M | -42.83M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 | -3.67 | -3.50 |
| EPS (Diluted) | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 | -3.67 | -3.50 |
| Shares Outstanding (Basic) | 151.72M | 147.10M | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 12.63M | 12.20M |
| Shares Outstanding (Diluted) | 151.72M | 147.10M | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 12.63M | 12.20M |
| EBITDA | -41.12M | -145.11M | -207.44M | -179.27M | -196.71M | -146.05M | -72.30M | -45.45M | -40.37M |
| Gross Margin | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% | 77.10% | 73.82% | 64.67% | 59.22% |
| Operating Margin | -20.62% | -90.83% | -133.33% | -108.03% | -135.39% | -155.33% | -92.15% | -89.39% | -115.68% |
| Net Margin | -21.48% | -89.12% | -132.29% | -108.03% | -134.30% | -148.63% | -80.65% | -83.44% | -111.40% |
This table shows 9 annual periods of Adaptive Biotechnologies's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ADPT's reporting calendar. What is a income statement?